NASDAQ:CCXI

Chemocentryx Stock News

etoro logo Buy CCXI
*Your capital is at risk
$10.24
+0.0150 (+0.147%)
At Close: Jun 03, 2026
These stocks are expected to put up big gains in a short amount of time.

Is It Too Late to Buy ChemoCentryx Stock?

07:18am, Thursday, 14'th Oct 2021
The stock surged after obtaining FDA approval for avacopan.

2 Super-Charged Growth Stocks to Buy Now

10:00am, Wednesday, 13'th Oct 2021
These two small drugmakers are poised for a long-winded growth spurt.

BZ Chart Of The Day: ChemoCentryx

11:43am, Monday, 11'th Oct 2021
There's an old saying on Wall Street that "gaps refill." It's true and it may be about to happen to shares of ChemoCentryx, Inc. (NASDAQ:CCXI).

CCXI Stock: Why It Increased Today

10:17am, Monday, 11'th Oct 2021
The stock price of ChemoCentryx Inc (NASDAQ: CCXI) increased by over 9% during intraday trading today. This is why it happened.

ChemoCentryx Appoints Rita I. Jain, M.D.

08:30am, Monday, 11'th Oct 2021
Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product

Why ChemoCentryx Stock Skyrocketed Today

05:40pm, Friday, 08'th Oct 2021
Investors are excited about the biotech's game-changing new drug.
On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for the treatment of ANCA vasculitis. Avacopan is an o
The broader market was mixed on Friday.
The stock price of ChemoCentryx Inc (NASDAQ: CCXI) increased by over 88% during intraday trading today. This is why it happened.
ChemoCentryx Inc (NASDAQ: CCXI) shareholders had every reason to be happy about on Friday morning. The shares of the group traded higher on Friday morning, thanks to the announcement made by the group
ChemoCentryx (CCXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more streng
Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% in premarket trading on Friday after the company said that it had received approval from the Food and Drug Administration for its ANCA-associated
The FDA has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis o
-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- -- Company to hold conference call at 8:30 a.m. Eastern Time --
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE